Whole blood
ApprovedBiologic
Whole blood is one of 87 biologic programs targeting Hemorrhage. It is currently in Approved.
3
Indications
6
Total Trials
1
Active Trials
86
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
137 competitors in Hemorrhage
#DrugCompanyPhaseTrials
1Cytotec
PfizerPhase 3
Cyklokapron
AAmring
Phase 3
Activase
RochePhase 3
Betadine
BBecton, Dickinson and Company
Phase 3
Virazole
CConrado Roberto Hoffmann Filho
Phase 3
Tylenol
KKenvue Brands
Phase 3
Glypressin
MMallinckrodt
Phase 3
Statins
SanofiPhase 3
Epoetin Beta
RochePhase 3
Ulipristal Acetate
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Whole blood. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company
- VVersailles Hospital